Trending...
- For Labor Day: Check out a poem about Labor and Manufacturing called "It used to be Made in America" - 208
- California prioritized fighting organized retail theft, those results are paying off with 36,000 arrests and $293 million in stolen goods recovered - 111
- California and the Australian state of Queensland ink new partnership to accelerate climate resilience, agricultural technology, and innovation - 108
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - Californer -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on The Californer
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on The Californer
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on The Californer
- Vallejo Home Prices Are Down—So Why Are So Many Homes Still Selling Over Asking?
- Newport Harbor and Corona del Mar Set for Battle of the Bay Showdown at Davidson Field
- City of Long Beach Issues Heat Alert and Advises Residents to Take Precautions Against Heat
- Five International Travel Deals for Seniors Start at Just $995
- Interpreters Unlimited Recognized Among San Diego's 2026 Companies That Care
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on The Californer
- IEI Launches Itten-E315, a 31.5-Inch Six-Color ePaper Display
- Impact & Influence April 2026: Joel Rodriguez Tirado on Renewal,Growth & Uncomfortable Conversations
- Franchise Operators Are Standardizing Compliance Across Every Location in 2026
- Impact & Influence March 2026: Joel Rodriguez Tirado - Why You're Still Waiting & The Power of Start
- New Comparison Helps Senior Travelers Weigh Overseas Adventure Travel Against Road Scholar
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on The Californer
- Skin Health Expert and Nurse Practitioner Blossom Inuenwi Launches 'The Glow Brief' Podcast
- AristoPup Grooming Launches "Fresh Start Grooming Days" to Help Palm Springs Animal Shelter Dogs
- New Edition of Bestselling Book Reveals How Consciousness Shapes Your Genes
- P&C Insurers -- Meet Me at ITC Vegas
- Happy Labor Day! California is the #1 for state for workers, #1 economy in the nation
- California: Governor Newsom proclaims Labor Day
- John Pape Releases Christian Single "The Road," Inspired by the Romans Road
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- TitleChain Foundation Issues Global Call to Build Public-Commons for Human-Controlled AI
- Lake Norman Philharmonic - Free Community Concert
- Los Angeles Massage Therapist Jesse Anoraj Places in Top Rankings at 2026 American Massage Championships
- City of Long Beach Issues Rain Advisory Due to Recent Showers
- Good Night, Oscar at North Coast Repertory Theatre
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- 99Websites Launches \$99 Done-for-You Website Service for Busy Professionals and Small Businesses
- Yalil Guerra's "Clave" to Receive World Premiere in New Symphonic Version at The Soraya
- solar bus stop led lighting for NCTD at 18 locations
- At 70, LA Woman Launches New E-Commerce Store One Year After Nerve Damage Left Her Unable to
- AI Visibility Campaign by 1stpage Reaches 800+ Citations Across Major AI Platforms in Four Months
- Apex Lane Logistics Surpasses 100-Truck Network as Southern California Freight Capacity Expands